Switch theme
Sign up to access all valuation multiples
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company’s next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
2001
102
LTM Revenue $32.9M
Last FY EBITDA -$63.3M
-$34.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mersana Therapeutics has a last 12-month revenue (LTM) of $32.9M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Mersana Therapeutics achieved revenue of $40.5M and an EBITDA of -$63.3M.
Mersana Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mersana Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $32.9M | XXX | $40.5M | XXX | XXX | XXX |
| Gross Profit | $32.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$63.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -156% | XXX | XXX | XXX |
| EBIT | -$76.2M | XXX | -$73.3M | XXX | XXX | XXX |
| EBIT Margin | -232% | XXX | -181% | XXX | XXX | XXX |
| Net Profit | -$73.6M | XXX | -$69.2M | XXX | XXX | XXX |
| Net Margin | -224% | XXX | -171% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mersana Therapeutics's stock price is $0.
Mersana Therapeutics has current market cap of $42.9M, and EV of -$34.7M.
See Mersana Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$34.7M | $42.9M | XXX | XXX | XXX | XXX | $-0.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mersana Therapeutics has market cap of $42.9M and EV of -$34.7M.
Mersana Therapeutics's trades at -0.9x EV/Revenue multiple, and 0.5x EV/EBITDA.
Equity research analysts estimate Mersana Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mersana Therapeutics has a P/E ratio of -0.6x.
See valuation multiples for Mersana Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $42.9M | XXX | $42.9M | XXX | XXX | XXX |
| EV (current) | -$34.7M | XXX | -$34.7M | XXX | XXX | XXX |
| EV/Revenue | -1.1x | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | -1.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMersana Therapeutics's last 12 month revenue growth is -7%
Mersana Therapeutics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.1M for the same period.
Mersana Therapeutics's rule of 40 is -458% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mersana Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mersana Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -7% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -156% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -458% | XXX | -163% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 180% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 281% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mersana Therapeutics acquired XXX companies to date.
Last acquisition by Mersana Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Mersana Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mersana Therapeutics founded? | Mersana Therapeutics was founded in 2001. |
| Where is Mersana Therapeutics headquartered? | Mersana Therapeutics is headquartered in United States of America. |
| How many employees does Mersana Therapeutics have? | As of today, Mersana Therapeutics has 102 employees. |
| Who is the CEO of Mersana Therapeutics? | Mersana Therapeutics's CEO is Dr. Martin H. Huber, M.D.. |
| Is Mersana Therapeutics publicy listed? | Yes, Mersana Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Mersana Therapeutics? | Mersana Therapeutics trades under MRSN ticker. |
| When did Mersana Therapeutics go public? | Mersana Therapeutics went public in 2017. |
| Who are competitors of Mersana Therapeutics? | Similar companies to Mersana Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Mersana Therapeutics? | Mersana Therapeutics's current market cap is $42.9M |
| What is the current revenue of Mersana Therapeutics? | Mersana Therapeutics's last 12 months revenue is $32.9M. |
| What is the current revenue growth of Mersana Therapeutics? | Mersana Therapeutics revenue growth (NTM/LTM) is -7%. |
| What is the current EV/Revenue multiple of Mersana Therapeutics? | Current revenue multiple of Mersana Therapeutics is -1.1x. |
| Is Mersana Therapeutics profitable? | Yes, Mersana Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
